These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer. Patel PH; Kockler DR Ann Pharmacother; 2008 Jan; 42(1):91-8. PubMed ID: 18094343 [TBL] [Abstract][Full Text] [Related]
7. Immunotherapy with Sipuleucel-T (APC8015) in patients with metastatic castration-refractory prostate cancer (mCRPC): a systematic review and meta-analysis. Botrel TE; Clark O; Pompeo AC; Bretas FF; Sadi MV; Ferreira U; Reis RB Int Braz J Urol; 2012; 38(6):717-27. PubMed ID: 23302410 [TBL] [Abstract][Full Text] [Related]
8. Sipuleucel-T (Provenge®) for castration-resistant prostate cancer. Di Lorenzo G; Ferro M; Buonerba C BJU Int; 2012 Jul; 110(2 Pt 2):E99-104. PubMed ID: 22177289 [TBL] [Abstract][Full Text] [Related]
9. Sipuleucel-T (APC8015) for prostate cancer. So-Rosillo R; Small EJ Expert Rev Anticancer Ther; 2006 Sep; 6(9):1163-7. PubMed ID: 17020451 [TBL] [Abstract][Full Text] [Related]
10. Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer. Shore ND; Mantz CA; Dosoretz DE; Fernandez E; Myslicki FA; McCoy C; Finkelstein SE; Fishman MN Cancer Control; 2013 Jan; 20(1):7-16. PubMed ID: 23302902 [TBL] [Abstract][Full Text] [Related]
11. Immunotherapy for metastatic prostate cancer: where are we at with sipuleucel-T? Lü C; Williams AK; Chalasani V; Martínez CH; Chin J Expert Opin Biol Ther; 2011 Jan; 11(1):99-108. PubMed ID: 21080858 [TBL] [Abstract][Full Text] [Related]
12. Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer. Beer TM; Bernstein GT; Corman JM; Glode LM; Hall SJ; Poll WL; Schellhammer PF; Jones LA; Xu Y; Kylstra JW; Frohlich MW Clin Cancer Res; 2011 Jul; 17(13):4558-67. PubMed ID: 21558406 [TBL] [Abstract][Full Text] [Related]
13. Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer. Sims RB Vaccine; 2012 Jun; 30(29):4394-7. PubMed ID: 22122856 [TBL] [Abstract][Full Text] [Related]
14. An analysis of leukapheresis and central venous catheter use in the randomized, placebo controlled, phase 3 IMPACT trial of Sipuleucel-T for metastatic castrate resistant prostate cancer. Flanigan RC; Polcari AJ; Shore ND; Price TH; Sims RB; Maher JC; Whitmore JB; Corman JM J Urol; 2013 Feb; 189(2):521-6. PubMed ID: 23253957 [TBL] [Abstract][Full Text] [Related]
15. Randomized phase II trial of sipuleucel-T immunotherapy preceded by sensitizing radiation therapy and sipuleucel-T alone in patients with metastatic castrate resistant prostate cancer. Twardowski P; Wong JYC; Pal SK; Maughan BL; Frankel PH; Franklin K; Junqueira M; Prajapati MR; Nachaegari G; Harwood D; Agarwal N Cancer Treat Res Commun; 2019; 19():100116. PubMed ID: 30682445 [TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial. James ND; Caty A; Borre M; Zonnenberg BA; Beuzeboc P; Morris T; Phung D; Dawson NA Eur Urol; 2009 May; 55(5):1112-23. PubMed ID: 19042080 [TBL] [Abstract][Full Text] [Related]
18. Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial. Schellhammer PF; Chodak G; Whitmore JB; Sims R; Frohlich MW; Kantoff PW Urology; 2013 Jun; 81(6):1297-302. PubMed ID: 23582482 [TBL] [Abstract][Full Text] [Related]
19. Sipuleucel-T for prostate cancer: the immunotherapy era has commenced. Buonerba C; Ferro M; Di Lorenzo G Expert Rev Anticancer Ther; 2011 Jan; 11(1):25-8. PubMed ID: 21166508 [TBL] [Abstract][Full Text] [Related]
20. Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Rini BI; Weinberg V; Fong L; Conry S; Hershberg RM; Small EJ Cancer; 2006 Jul; 107(1):67-74. PubMed ID: 16736512 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]